Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiken Biomedical CoTPE:7780 +1.20%22 EV-to-EBIT is 14.64 as of Aug. 17, 2026, which is 50% below its 10-year median of 29.27. GuruFocus rates TPE:7780 with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 1,559 Consumer Packaged Goods companies, Daiken Biomedical Co ranks worse than 71.2% on this metric.
Daiken Biomedical Co (TPE:7780) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Daiken Biomedical Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$9,211 Mil.
Daiken Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$551 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiken Biomedical Co EV-to-EBIT Related Terms
Daiken Biomedical Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Daiken Biomedical Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Daiken Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Biomedical Co EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Daiken Biomedical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Daiken Biomedical Co's EV-to-EBIT falls into.
Daiken Biomedical Co's current Enterprise Value is NT$8,061 Mil.
Daiken Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$551 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiken Biomedical Co (TPE:7780) has a EV-to-EBIT of 14.64 as of Aug. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Daiken Biomedical Co and its competitors. This is 50% below median its historical median of 29.27. Over the past decade, Daiken Biomedical Co's EV-to-EBIT has ranged from 16.72 to 68.03. According to the industry distribution chart, Daiken Biomedical Co ranks #1110 out of 1559 companies in the Consumer Packaged Goods industry, placing it in the top 71.2%.
Is Daiken Biomedical Co's EV-to-EBIT too high?
Daiken Biomedical Co's current EV-to-EBIT of 14.64 is 50% below median its 10-year median of 29.27. Over the past 10 years, this metric has ranged from a low of 16.72 to a high of 68.03. The Consumer Packaged Goods industry median EV-to-EBIT is 12.23. Daiken Biomedical Co's value of 14.64 is 19.7% above this industry median. Based on the distribution chart, Daiken Biomedical Co ranks #1110 out of 1559 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Daiken Biomedical Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Daiken Biomedical Co's EV-to-EBIT compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Daiken Biomedical Co ranks #1110 out of 1559 companies for EV-to-EBIT. This places Daiken Biomedical Co in the lower half of its industry. The industry median EV-to-EBIT is 12.23. Daiken Biomedical Co's value of 14.64 is 19.7% above this benchmark. Historically, Daiken Biomedical Co's own EV-to-EBIT has ranged from 16.72 to 68.03 over the past decade. While the company's 10-year median is 29.27 vs. the industry median of 12.23, Daiken Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Consumer Packaged Goods company?
The median EV-to-EBIT among Consumer Packaged Goods companies is 12.23, based on 1,559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Biomedical Co's current EV-to-EBIT of 14.64 is 19.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Daiken Biomedical Co and its competitors. For the Consumer Packaged Goods industry, the median EV-to-EBIT is 12.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Biomedical Co's current EV-to-EBIT is 14.64, which is 50% below median its own 10-year median of 29.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Biomedical Co stock overvalued right now?
Daiken Biomedical Co (TPE:7780) has a current EV-to-EBIT of 14.64. The current EV-to-EBIT is 14.64, which is 50% below median its 10-year median of 29.27 and 19.7% above the Consumer Packaged Goods industry median of 12.23. Daiken Biomedical Co's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Daiken Biomedical Co (TPE:7780), the current EV-to-EBIT is 14.64 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Daiken Biomedical Co Ltd is engaged in Research, development, and sales of health food. Its products include fish oil capsules, collagen powder, collagen drinks, natto capsules, and mint leaf capsules. The companies reportable operating segment consists solely of the e-commerce division.
22GF Score
Get the complete analysis for TPE:7780
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7780 has been successfully added to your 
